MedWatch has interwied CEO Nils Brünner about the new and exiting reserach collaboration between Scandion Oncology og Alligator Biosciences.
The aim for this reserach project is to obtain proof-of-concept that SCO-101 in combination with the immuneoncology drug mitazalimab can lead to improved anti-cancer response.
The interview can be found here:
Svensk biotekselskab skal give Scandion Oncology fodfæste inden for immunonkologi: https://medwatch.dk/Medicinal___Biotek/article12192107.ece
